| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis.
|
Nat Med
|
2003
|
4.69
|
|
2
|
Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells.
|
Cell Stem Cell
|
2009
|
4.52
|
|
3
|
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
|
Cancer Cell
|
2008
|
4.51
|
|
4
|
Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells.
|
Cell Stem Cell
|
2010
|
4.21
|
|
5
|
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment.
|
Nat Med
|
2002
|
4.00
|
|
6
|
Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
|
J Natl Cancer Inst
|
2005
|
3.58
|
|
7
|
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
|
Cancer Res
|
2003
|
3.09
|
|
8
|
Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
|
Cancer Res
|
2007
|
1.73
|
|
9
|
The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.
|
Int J Cancer
|
2006
|
1.54
|
|
10
|
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.
|
J Biol Chem
|
2005
|
1.41
|
|
11
|
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
|
Blood
|
2003
|
1.35
|
|
12
|
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
|
J Biol Chem
|
2003
|
1.33
|
|
13
|
Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
|
Clin Cancer Res
|
2010
|
1.28
|
|
14
|
Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
|
Clin Cancer Res
|
2008
|
1.24
|
|
15
|
Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy.
|
Invest Ophthalmol Vis Sci
|
2002
|
1.15
|
|
16
|
DEGA/AMIGO-2, a leucine-rich repeat family member, differentially expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal stability, cell adhesion/migration and tumorigenicity.
|
Oncogene
|
2004
|
1.14
|
|
17
|
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.
|
Int J Cancer
|
2002
|
1.09
|
|
18
|
Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
|
Mol Cancer Ther
|
2005
|
1.09
|
|
19
|
Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines.
|
Mol Cancer Ther
|
2008
|
1.06
|
|
20
|
Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
|
Cancer Res
|
2005
|
1.00
|
|
21
|
Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.
|
J Biol Chem
|
2003
|
0.99
|
|
22
|
Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
|
Cancer Res
|
2009
|
0.99
|
|
23
|
Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.
|
Neoplasia
|
2009
|
0.99
|
|
24
|
Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.
|
Curr Cancer Drug Targets
|
2002
|
0.98
|
|
25
|
Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C.
|
J Cell Sci
|
2004
|
0.97
|
|
26
|
Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
|
Clin Cancer Res
|
2009
|
0.90
|
|
27
|
Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.
|
Blood
|
2004
|
0.87
|
|
28
|
Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.
|
J Immunol Methods
|
2002
|
0.86
|
|
29
|
The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
|
Biochem Biophys Res Commun
|
2004
|
0.85
|
|
30
|
A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3.
|
Mol Cancer Ther
|
2005
|
0.85
|
|
31
|
IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
|
Cancer Res
|
2006
|
0.81
|
|
32
|
Di-diabody: a novel tetravalent bispecific antibody molecule by design.
|
J Immunol Methods
|
2003
|
0.79
|
|
33
|
Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
|
Neoplasia
|
2011
|
0.79
|
|
34
|
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
|
Anticancer Res
|
2009
|
0.78
|
|
35
|
Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.
|
Leuk Lymphoma
|
2004
|
0.78
|
|
36
|
Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
|
Anticancer Res
|
2011
|
0.75
|
|
37
|
Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed.
|
Hum Antibodies
|
2004
|
0.75
|